TRANXENE (clorazepate dipotassium) - Premedication

Reason for request

Clinical Benefit

Insufficient

The Committee deems that the clinical benefit of TRANXENE (clorazepate dipotassium) 20 mg/2 mL solution for injection is insufficient to justify public funding cover in premedication before certain functional investigations in adults in view of the available alternatives.

Clinical Added Value

Not applicable